Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential

9. Boston Scientific Corporation (NYSE:BSX)

Farallon Capital’s Stake: $709 Million

Analyst Upside Potential: 21%

Boston Scientific Corporation (NYSE:BSX) has consistently featured in the 13F portfolio of Farallon Capital since the third quarter of 2020. Back then, this position comprised just under 8.3 million shares. The fund steadily added to this stake until the fourth quarter of 2021, growing it to over 16.8 million shares. Thereafter, it started trimming the stock. Filings for the fourth quarter of 2025 show that the fund owned 7.4 million shares in the firm, up more than 56% compared to filings for the previous quarter. The company develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

READ ALSO: 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026.

Boston Scientific Corporation (NYSE:BSX) is attracting interest from elite investors due to crown jewel products, which dominated headlines at the Heart Rhythm 2026 conference. The first of these was FARAPULSE PFA. New clinical data demonstrated that this device is superior to traditional antiarrhythmic drugs for treating persistent atrial fibrillation. The second was the success of WATCHMAN. The CHAMPION-AF study recently confirmed that the WATCHMAN device is a safe and effective first-line alternative to blood thinners, which opens up a significantly larger patient market. In its Q1 2026 earnings report, Boston Scientific beat revenue expectations, $5.20 billion versus $5.17 billion, but lowered its full-year guidance.